Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Princess Noura bint Abdul Rahman University, Riyadh, Saudi Arabia.
The Tunisian Center of Early Intervention in Psychosis, Psychiatry Department "Ibn Omrane", Tunisia; Tunis El Manar University, Faculty of Medicine of Tunis, Tunisia.
Sleep Med. 2022 Dec;100:7-23. doi: 10.1016/j.sleep.2022.06.020. Epub 2022 Aug 8.
There have been no previous meta-analytic studies that have looked at the prevalence of insomnia symptoms in different COVID-19 groups using a single assessment instrument to evaluate insomnia symptoms while maintaining data homogeneity. The current review's associated goal is to undertake an individual participant data (IPD) analysis to further investigate past meta-analyses, a method that has been shown to be more robust than standard meta-analyses.
Only studies that used the Insomnia Severity Index (ISI) to assess insomnia are used in this analysis. The IPDMA was performed and registered in PROSPERO in compliance with the PRISMA IPD Statement (CRD42021275817). From November 2019 to August 2021, researchers explored seventeen databases and six preprint services for relevant studies.
The pooled estimate of insomnia symptoms (subthreshold and clinically significant) was 52.57%. An estimated 16.66% of the population suffered from clinically significant insomnia, of which 13.75% suffered from moderate insomnia, and 2.50% suffered from severe insomnia. The different populations' grouping had no statistically significant differences in the prevalence of insomnia symptoms. Insomnia symptoms did not appear to be associated with age or sex.
Our findings imply that the COVID-19 pandemic is linked to a significant rise in subthreshold insomnia symptoms, but not to moderate or severe insomnia. Educating people from all walks of life about the importance of sleep and the risk of acquiring insomnia symptoms during this or future pandemics should be a top concern.
此前尚无研究使用单一评估工具评估失眠症状，同时保持数据同质性，对不同 COVID-19 群体的失眠症状发生率进行荟萃分析。本综述的目的是采用个体参与者数据（IPD）分析进一步调查以往的荟萃分析，这种方法已被证明比标准荟萃分析更稳健。
本分析仅使用失眠严重程度指数（ISI）评估失眠的研究。按照 PRISMA IPD 声明（CRD42021275817）的要求，在 PROSPERO 中进行并注册了 IPDMA。从 2019 年 11 月至 2021 年 8 月，研究人员对 17 个数据库和 6 个预印本服务进行了相关研究的探索。
失眠症状（亚临床和临床显著）的合并估计值为 52.57%。估计有 16.66%的人群患有临床显著失眠症，其中 13.75%患有中度失眠症，2.50%患有严重失眠症。不同人群分组的失眠症状发生率无统计学差异。失眠症状似乎与年龄或性别无关。
我们的研究结果表明，COVID-19 大流行与亚临床失眠症状的显著增加有关，但与中度或重度失眠无关。教育各界人士了解睡眠的重要性以及在此次或未来大流行期间罹患失眠症状的风险应是重中之重。
